Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic

CMAJ

Volumn 192, Issue 15, 2020, Pages E405-E407

  Cheng, Matthew P ^a,b   Lee, Todd C ^a,b   Tan, Darrell H S ^c,d   Murthy, Srinivas ^e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CHLOROQUINE; LOPINAVIR PLUS RITONAVIR; MACROLIDE; REMDESIVIR; STEROID;

CANADA; CLINICAL TRIAL PROTOCOL; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EVIDENCE BASED MEDICINE; FUNDING; HUMAN; NOTE; PANDEMIC; POST EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH PRIORITY; SARS-RELATED CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; BETACORONAVIRUS; DRUG APPROVAL; GOVERNMENT REGULATION; METHODOLOGY; VIRUS PNEUMONIA;

BETACORONAVIRUS; CANADA; CORONAVIRUS INFECTIONS; DRUG APPROVAL; GOVERNMENT REGULATION; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85083330725     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.200438     Document Type: Note

References (12)

1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Feb. 18 [Epub ahead of print]. doi: 10.1016/S2213-2600(20)30076-X.
3. Herrera-Perez D, Haslam A, Crain T, et al. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. eLife 2019; 8:e45183. doi: 10.7554/eLife.45183.
4. Dyer O. What did we learn from Tamiflu?. BMJ 2020; 368:m626.
5. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55:105924.
6. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020 Mar. 18 [Epub ahead of print]. doi: 10.1056/NEJMoa2001282.
7. Gobat NH, Gal M, Butler CC, et al. Talking to the people that really matter about their participation in pandemic clinical research: A qualitative study in four European countries. Health Expect 2018; 21:387-95.
8. Gobat N, Butler CC, Mollison J, et al. What the public think about participation in medical research during an influenza pandemic: An international crosssectional survey. Public Health 2019; 177:80-94.
9. Mulangu S, Dodd LE, Davey RT Jr., et al.; PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381:2293-303.
10. REMAP-CAP: A Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia [main page]. Available: www. remapcap.org (accessed 2020 Mar. 3).
11. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017; 389:505-18.
12. Kretzschmar M, van den Hof S, Wallinga J, et al. Ring vaccination and smallpox control. Emerg Infect Dis 2004; 10:832-41.